Novartis (NYSE:NVS) shares are in the green in the pre-markets session today after two phase 3 clinical trials showed its Consentyx demonstrated superior efficacy over placebo in symptoms of skin disease hidradenitis suppurativa (HS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HS affects about one in 100 people globally causing painful lesions. The company has submitted data from the two trials to European authorities and plans to submit it in the U.S. by the end of the year as well.
The drug showed rapid relief from the ailment as well as a favorable safety profile. Long-term results from these trials are expected in 2023. Additionally, Novartis also aims to expand the drug to 10 indications.
Read full Disclosure